No Data
IMMUNOTECH-B: 2024 ANNUAL REPORT
IMMUNOTECH-B (06978): Yu Xiaohui has been appointed as a non-executive Director and a member of the Audit Committee.
IMMUNOTECH-B (06978) announced that, starting from April 25, 2025: Xiao Hui has been appointed as a non-executive...
Immunotech Biopharm's 2024 Loss Narrows
Hong Kong Stock Announcement Gold Mining | CHINA OVERSEAS reported annual performance with a profit attributable to Shareholders of 15.636 billion yuan, a decrease of 38.95% year-on-year.
FOSUN PHARMA (02196) intends to invest 0.27 billion yuan to subscribe for 0.105 billion newly issued shares of UnitedHealth; Chugai Pharmaceutical-B (02171): A summary of the research results of SRK-015 injection has been accepted for an oral presentation at the 2025 ASCO Annual Meeting.
IMMUNOTECH-B (06978.HK) reported a loss of 0.187 billion yuan for the 2024 fiscal year, a year-on-year decrease of 44.18%.
Glory Financial reported on March 31 that IMMUNOTECH-B (06978.HK) announced its annual performance. For the fiscal year ending December 31, 2024, the group's other income amounted to RMB 33.788 million, representing a year-on-year growth of 220.36%; the annual loss attributable to shareholders was RMB 0.187 billion, narrowing by 44.18% year-on-year; basic loss per share was RMB 0.36. The group's R&D expenses decreased from approximately RMB 0.177 billion for the fiscal year ending December 31, 2023, by about 13.0% to approximately RMB 0.154 billion for the fiscal year ending December 31, 2024, mainly.
Express News | Immunotech Biopharm FY Pretax Profit RMB -186.4 Million
